Comparison of response rates and drug costs during maintenance therapy with adalimumab versus ustekinumab in patients with moderate to severe psoriasis

P3307

  • Signorovitch, James
  • Kantor, Evan
  • Mulani, Parvez
  • Bao, Yanjun

  • 1Analysis Group, Boston, MA, United States

    2Analysis Group, Boston, MA, United States

    3Abbott Laboratories, Abbott Park, IL, United States

    4Abbott Laboratories, Abbott Park, IL, United States

Commercial support: This study is sponsored by Abbott Laboratories.

Journal of the American Academy of Dermatology 62(3):p AB125, March 2010.
Copyright © 2010 by Mosby, Inc.